Simone Leyden

Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals

Simone Leyden, Teodora Kolarova, Catherine Bouvier et al. · International Journal of Cancer · 2019 · 30 citations · Full text

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.

Nick Pavlakis, David Ransom, David Wyld et al. · Journal of Clinical Oncology · 2022 · 28 citations

Gastroenterology, Pathology, Midgut Neuroendocrine Tumours +24

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of ¹⁷⁷Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).

Nick Pavlakis, David Ransom, David Wyld et al. · Journal of Clinical Oncology · 2020 · 26 citations

Gastrointestinal Pharmacology, Gastroenterology, Pathology +22

Pivotal phase III COMPOSE trial will compare ¹⁷⁷Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors.

Diane Reidy‐Lagunes, Namrata Vijayvergia, Daniel M. Halperin et al. · Journal of Clinical Oncology · 2022 · 24 citations

Surgical Oncology, Best Standard, Pathology +16

The Economic Impact on Australian Patients with Neuroendocrine Tumours

Louisa G. Gordon, Thomas M. Elliott, Kate Wakelin et al. · Patient · 2020 · 18 citations

Neuro-oncology, Health Economics, Medicine +6